Shoreline Biosciences, Inc. Appoints Vanessa L. Jacoby as Chief Financial Officer

Shoreline Biosciences, Inc. appointed Vanessa L. Jacoby as Chief Financial Officer. She brings more than twenty years of experience in the Biotechnology and Life Science sectors. Before joining Shoreline, Vanessa served as Chief Accounting Officer of Avidity Biosciences, Inc. Before that, she was Vice President, Finance at PharmAkea, which was acquired by Galecto, Inc. in 2019. Prior, she served as a Director of Accounting and Controller at BCI and held Senior Financial roles at Artes Medical and Verenium. Before joining the industry, Vanessa was an auditor for Ernst & Young and she is a certified public accountant with the State of California.
 
Shoreline Biosciences, Inc. is a privately held biotechnology company based in La Jolla, CA. Employing approximately 15 people, Shoreline’s proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.